Journal:

Article Title: AN ELISA-BASED METHOD TO QUANTIFY OSTEOCALCIN CARBOXYLATION IN MICE

doi: 10.1016/j.bbrc.2010.06.008

Figure Lengend Snippet: (A) The specificity of the different goat antibodies were tested by western blotting on dot blot membranes. GLA-OCN: fully carboxylated osteocalcin. GLU-OCN: uncarboxylated osteocalcin.

Article Snippet: GLU, GLA13 and total mouse osteocalcin ELISA Antibody Coating Buffer (CB1), ELISA Wash Buffer (WB1), General Blocker Buffer (BB1), General Assay Diluent (AD1) and Stop Solution for TMB (STOP1) were all obtained from ImmunoChemistry Technologies.

Techniques: Western Blot, Dot Blot

Journal:

Article Title: AN ELISA-BASED METHOD TO QUANTIFY OSTEOCALCIN CARBOXYLATION IN MICE

doi: 10.1016/j.bbrc.2010.06.008

Figure Lengend Snippet: (A) Quantitative measurement of GLU-OCN, GLA13-OCN and total osteocalcin in the supernatant of primary osteoblasts cultures (pOB) treated with a vehicle or with warfarin. *** p < 0.001 compared to vehicle treated osteoblasts.

Article Snippet: GLU, GLA13 and total mouse osteocalcin ELISA Antibody Coating Buffer (CB1), ELISA Wash Buffer (WB1), General Blocker Buffer (BB1), General Assay Diluent (AD1) and Stop Solution for TMB (STOP1) were all obtained from ImmunoChemistry Technologies.

Techniques:

Journal:

Article Title: AN ELISA-BASED METHOD TO QUANTIFY OSTEOCALCIN CARBOXYLATION IN MICE

doi: 10.1016/j.bbrc.2010.06.008

Figure Lengend Snippet: (A) Quantitative measurement of GLU-OCN, GLA13-OCN and total osteocalcin in serums from 2 months old wild type (WT) and Ocn −/− mice. All three forms were undetectable (UN) in Ocn −/− serums.

Article Snippet: GLU, GLA13 and total mouse osteocalcin ELISA Antibody Coating Buffer (CB1), ELISA Wash Buffer (WB1), General Blocker Buffer (BB1), General Assay Diluent (AD1) and Stop Solution for TMB (STOP1) were all obtained from ImmunoChemistry Technologies.

Techniques:

Journal: Nature Communications

Article Title: Structure-guided design of endosomolytic chloroquine-like lipid nanoparticles for mRNA delivery and genome editing

doi: 10.1038/s41467-025-59501-y

Figure Lengend Snippet: a The z-average hydrodynamic size distribution (left panel) and representative transmission electron microscopy images (right panel) of ecoLNPs. b In vitro delivery performance of ecoLNPs during storage at 4 °C. ecoLNPs containing 200 ng of eGFP mRNA were stored at 4 °C for different storage times and their in vitro delivery performance was estimated by the intensity of green fluorescence originating from ecoLNPs-treated 293T cells. Scale bar, 50 µm. c Susceptibility of ecoLNPs-encapsulated eGFP mRNA to serum or RNase A. Free eGFP mRNA was used as a control group. The green and red triangles indicate the location of bands of ecoLNPs-encapsulated and free mRNA, respectively. d Hemolytic activity induced by different concentrations of ecoLNPs at pH of 5.4 and 7.4 ( n = 3 biological replicates, two-way ANOVA with Tukey’s multiple comparison test). The concentration of ecoLNPs used for assessment of in vitro delivery activity was defined as 1×. e Dose-response and time-course analyses of 293T cells exposure to eGFP mRNA-loaded ecoLNPs. MFI, mean fluorescence intensity. f A comparison of eGFP mRNA delivery efficiency of ecoLNPs with Lipofectamine 2000 (Lipo2k) and Lipofectamine MessengerMAX (LipoMMAX) in 293T (left panel) and THP-1 cells (right panel) by flow cytometry. PBS-treated cells were used to differentiate positive and negative events. g A comparison of β-gal mRNA delivery efficiency of ecoLNPs with Lipo2k and LipoMMAX in 293T cells by in situ β-galactosidase staining (top panel; scale bar, 100 µm) and a comparison of mCherry mRNA delivery efficiency by fluorescence imaging (bottom panel; scale bar, 50 µm). h Quantitative analysis of both β-gal mRNA and mCherry mRNA delivery efficiency using a colorimetric method (left panel) and flow cytometry (right panel), respectively ( n = 3 biological replicates, one-way ANOVA with Tukey’s multiple comparison test). MFI, mean fluorescence intensity. Fluorescent images of 3D cells treated with eGFP mRNA- ( i , top panel), mCherry mRNA- ( i , bottom panel), or dual mRNA- ( j ) loaded ecoLNPs. Scale bar, 50 μm. For all relevant panels, data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: For three-dimensional cell culture, 293T cells (1 × 10 3 cells per well) were seeded in a 96-well round-bottom plate coated with 3D cell culture coating solution (Beyotime) and treated with 50 ng of ecoLNPs-encapsulated eGFP mRNA, mCherry mRNA, or their combinations (25 ng plus 25 ng).

Techniques: Transmission Assay, Electron Microscopy, In Vitro, Fluorescence, Control, Activity Assay, Comparison, Concentration Assay, Flow Cytometry, In Situ, Staining, Imaging

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Schematic representation of the principle of SARS-CoV-2-RBD neutralizing ELISA assay2.2. Assay Optimization

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Standard curve of anti-SARS-COV-2-RBD nAbs for the in-house developed SARS-COV-2-RBD neutralizing ELISA assay

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Mean ± standard deviation of OD values of different anti-SARS-COV-2-RBD neutralizing antibody standards generated by the designed neutralizing ELISA kit

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Standard Deviation, Generated, Enzyme-linked Immunosorbent Assay, Concentration Assay, Negative Control, Positive Control

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Cut-off value results of the in-house neutralizing ELISA; A) Optimized ROC analysis cut-off value of positive and B) Concentration and log concentration limits for the optimal established cut-off in this assay

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Receiver operating characteristic curve analysis for the optimal cut-off value for detecting the positive anti-SARS-COV-2-RBD neutralizing antibodies using the in-house developed neutralizing ELISA kit

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Serum panels using the in-house designed SARS-COV-2-RBD neutralizing ELISA assay; A) Positive control samples for the assay validation and B) Negative control samples for the assay validation

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Enzyme-linked Immunosorbent Assay, Positive Control, Biomarker Discovery, Negative Control, Concentration Assay

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Agreement of the results between the in-house SARS-COV-2-RBD neutralizing ELISA assay and gold standard test at the in-house established cut-off

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Archives of Razi Institute

Article Title: Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

doi: 10.22092/ARI.2021.356677.1890

Figure Lengend Snippet: Validation parameters of the in-house SARS-COV-2-RBD neutralizing ELISA assay

Article Snippet: Preparation of Working Human Angiotensin-Converting Enzyme 2 Protein Solution To immobilize the hACE2 protein at 400 ng/well in 100 μl of 1X working Coating Buffer on the microtiter plates wells, a calculated volume from Stock solution vial of Recombinant His-Tag-Human ACE2 protein in a concentration of 2.8 mg/ml (Raybiotech) was diluted immediately before usage with the prepared 1X working coating buffer from 5X stock ELISA Plate Coating Buffer (Elabscience) to a required volume at the appropriate concentration (4 ng/μl), which was determined in the initial experiments.

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay